We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Servision | SEV | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.85 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.85 | 0.85 |
| Top Posts |
|---|
Posted at 20/2/2018 12:02 by tomboyb Looking at the last RNS I wonder what made them decide to bring out this RNS -New investor decided not to invest or so at a significantly lower level - Cascade who paid over 11p don't agree - CEO wishes to pick up the tech for a song? Debt could be converted to equity but price not agreed? Quite a few questions and forum busier at the LSE - |
Posted at 19/5/2017 12:11 by ny boy Patient investors will be rewarded soon |
Posted at 01/3/2017 14:08 by the stigologist lol Babbler is long and wrong and desperateone of oldest sayings in stockmarkets if it sounds too good to be true it probably is ask yourself would a real investor pay a 400% premium to a stock price ? |
Posted at 22/2/2017 11:39 by cautoussid Cascade is a fund set up by a small group of private investors, based in New York, who focus on the healthcare, biotechnology and technology sectors. |
Posted at 22/2/2017 10:04 by sh1984 I have never seen another placing done before at such a premium...almost 300%....wow. Something has to be brewing and I am sure the investors buying shares at 11.40 will be looking at returns too. 20p perhaps?I see that the share price was 30p plus previously. |
Posted at 26/1/2016 10:39 by the stigologist SEV looks like another one of these Israeli con companies like PTVHave to ask yourselves when Israel has it's own capital markets why do they need to list on AIM other than to fleece the most gullible investors on the least regulated market in the World ? |
Posted at 20/10/2015 14:04 by aim_trader Servision CEO Gidon Tahan will be presenting to investors at the Tech Capital Conference on the 26th October in London. To register, please click here |
Posted at 02/6/2015 14:25 by bill182 Can't seem to post the link, but it is a new interview with the CEO by Proactive Investors. Very positive indeed! |
Posted at 03/8/2014 22:13 by euclid5 Mobileye Record IPO Defeats Global Selloff as Shares Soar Mobileye NV (MBLY), which makes software to avoid car accidents, overcame the worst global stock-market selloff in almost five months to raise $890 million last week, a record for an Israeli company going public in the U.S. The shares soared 48 percent to $37 in New York on their first day of trading on Aug. 1 after the company and existing shareholders sold 35.6 million shares for $25 each, according to a Mobileye statement. That was above the high end of the $21 to $23 marketed range. The Jerusalem-based company weathered the biggest rout in global equities since March and a weekly drop of 1.8 percent in the Bloomberg Israel-US Equity Index. Mobileye commanded more money from investors while only three of four Israeli biotechnology firms completed planned initial public offerings last week, with all either downsizing or pricing below their target range. "Some of these IPOs which are in special industries are trading in their own world," Josef Schuster, the founder of IPOX Schuster LLC in Chicago, said by phone Aug. 1. "In the last week or two you have seen some of the IPO stocks really trading independently of the market." Sharron Silvers, a New York-based spokeswoman for Mobileye, declined via e-mail to comment on the trading. The company, which counts luxury electric-carmaker Tesla Motors Inc. as a customer, posted 2013 net income of $19.9 million following two years of losses, according to the prospectus. Revenue in 2013 was $81.2 million, more than double the figure from 2012. Revenue Growth Mobileye rallied after boosting its deal because investors see it as a high-growth technology company with proven sales within the auto industry, said Brian Krawez, who oversees $3 billion at Scotts Valley, California-based Scharf Investments LLC. "A lot of tech companies that don't make a lot of money such as Mobileye and Tesla that have high revenue growth, tend to get really high valuations," Krawez said by phone Aug. 1. "To justify this valuation, the company has to hit a huge home run." The MSCI All-Country World Index slid 2.4 percent last week as Mobileye completed its stock offering. Stocks tumbled after companies from Exxon Mobil Corp. to Samsung Electronics Co. reported results that disappointed investors, Argentina defaulted and Banco Espirito Santo SA in Portugal was ordered to raise capital. Israel's TA-25 benchmark slipped 0.4 percent in the five days ended July 31 as fighting between Israel and Hamas continued. The gauge closed little changed at 1,392.98 in Tel Aviv yesterday. Biotech IPOs Mapi Pharma Ltd. (MAPI), which makes treatments for multiple sclerosis, postponed plans to raise $18 million in an IPO last week, according to data compiled by Bloomberg. Vascular Biogenics Ltd., which develops cancer drugs, raised $64.8 million, selling 5.4 million shares for $12 a share, below the marketed price range of $13 to $15, according to a regulatory filing. MacroCure Ltd. (MCUR) and Bio Blast Pharma Ltd. also raised less than planned. "There's a difference between a hot market where you can do anything, and a smart market that says, is there a catalyst behind this, is there an unmet medical need?" Jason Kolbert, an analyst at Maxim Group LLC in New York, said by phone Aug. 1. "The market is beginning to differentiate between just anything, which is where we were in January to March, to selective." Mobileye's IPO was the 10th-largest in the U.S. this year and surpassed Partner Communication Ltd.'s share sale of $525 million in October 1999 to become the biggest by an Israeli company in the U.S. Mobileye Founders Founded by Hebrew University professor Amnon Shashua and Ziv Aviram 15 years ago, Mobileye makes a chip and a system that alert drivers to pedestrians and unintended lane departures. The company's products will help enable hands-free driving on the highway by 2016, according to the filing. As of March 31, Mobileye's technology was installed in about 3.3 million cars made by manufacturers from Honda Motor Co. to Tesla, the company estimates. Mobileye's software is distributed through auto-parts suppliers such as TRW Automotive Holdings Corp. (TRW) and Delphi Automotive Plc. The record deal size represents a new wave of Israeli startups that are turning down strategic partnerships and acquisition offers to grow independently, said Adam Fisher, a partner in the Herzliya, Israel-based office of Bessemer Venture Partners. "The companies we back seem to be more ambitious than ever before, much bigger markets, they don't sell out as early," Fisher, who isn't an investor in Mobileye, said by phone on July 28. "It's a new breed of Israeli tech that's different from the tech of the 90's." hxxp://www.bloomberg |
Posted at 16/7/2014 19:18 by euclid5 from the YE results below this indicates that the placees may pull out of the fund raising & agree a lower price as they never sent back their subscription letters"The Company is at an advanced stage of an equity fundraise with new investors through a subscription of new ordinary shares in the Company. As of today the Company has received approximately £625,000 in cash from these private investors but no shares have yet been issued or allotted. The issue price for the subscription is expected to be 5.2 pence per share" "The Company has not yet received signed subscription letters from the investors. Once the investors have entered into subscription letters with the Company, the Company will allot the shares and make application for the listing of the new shares to trading on AIM. The fundraise will be undertaken within the Company's existing share authorities" hxxp://www.investega |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
